Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Maryland Healthcare Reporter.
Press releases published on June 18, 2025
Diagonal’s First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
GlobeNewswire
·
June 18, 2025
WATERTOWN, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with clustering antibodies that address the underlying cause of intractable genetic diseases, today announced …
Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data
GlobeNewswire
·
June 18, 2025
Phase 3 TransportNPC study to continue based on the independent DMC review of safety and efficacy data at prespecified 48-week interim analysis Data on the investigational candidate Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin), indicates that it is …
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing
GlobeNewswire
·
June 18, 2025
Robust intellectual property portfolio, built over more than a decade, designed to protect core innovations for treating metabolic diseases New U.S. patents strengthen Fractyl’s leadership in metabolic innovation by expanding its patent coverage of …
Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
GlobeNewswire
·
June 18, 2025
Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of …
Sharps Technology Advances Shipment Under $50 Million SoloGard Supply Agreement and Begins Manufacturing Facility Upgrades
GlobeNewswire
·
June 18, 2025
Second commercial delivery underway as part of multi-year contract with leading U.S. healthcare partner Strategic manufacturing upgrades drive scalability, efficiency, and increases capacity to support production growth NEW YORK, June 18, 2025 (GLOBE …
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
GlobeNewswire
·
June 18, 2025
Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year1 with 60% of patients experiencing relapse or death within 12 months2 Management releases …
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)
GlobeNewswire
·
June 18, 2025
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that data from across the SYMBRAVO® (meloxicam …
BPGbio Announces Presentation of Preliminary Clinical Data of Investigational BPM31510 for Primary CoQ10 Deficiency
GlobeNewswire
·
June 18, 2025
BPM31510 provides encouraging evidence of the potential for transformative benefit for a disease with high unmet need, supporting further development. The Company plans to seek guidance in Q3 2025 from the FDA regarding the development of BPM31510 for PCQD …
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates
GlobeNewswire
·
June 18, 2025
Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND filing on track for the second half of 2025; with Phase I …
Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board
GlobeNewswire
·
June 18, 2025
NEW YORK and PARIS, June 18, 2025 (GLOBE NEWSWIRE) -- Rarecells, Inc., a leader in liquid biopsy technology, is pleased to announce the appointment of Dr. Rita Shaknovich to its Scientific Advisory Board. Dr. Shaknovich brings over 20 years of leadership …
TOLREMO therapeutics Announces Strengthening of Leadership: Alessandra Cesano Joins Board of Directors, Florian D. Vogl Appointed Chief Medical Officer
GlobeNewswire
·
June 18, 2025
Basel, Switzerland – June 18, 2025 - TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company developing TT125-802, a best-in-class CBP/p300 bromodomain inhibitor for the treatment of solid tumors and multiple myeloma, today announced key …
Smith+Nephew and Standard Health partner on first Orthopaedic Ambulatory Surgery Centre in the UK
GlobeNewswire
·
June 18, 2025
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a strategic partnership with Standard Health www.standardhealth.co.uk to support the development of the first-ever Orthopaedic Ambulatory Surgery Centre in the UK. …
Bavarian Nordic sælger Priority Review Voucher for USD 160 mio.
GlobeNewswire
·
June 18, 2025
KØBENHAVN, Danmark, 18. juni 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået aftale om salg af sin Priority Review Voucher (PRV) for USD 160 mio. kontant. Bavarian Nordic blev tildelt voucheren i februar 2025 i forbindelse …
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million
GlobeNewswire
·
June 18, 2025
COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of USD 160 million. Bavarian Nordic was awarded the PRV in …
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
GlobeNewswire
·
June 18, 2025
Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will …
Draig Therapeutics Launches with $140 Million (£107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders
GlobeNewswire
·
June 18, 2025
Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric disorders with a rich pipeline of novel, potentially transformative treatments Proceeds will fund four clinical studies: two related to the …
Biomea Fusion Announces Pricing of Public Offering of Securities
GlobeNewswire
·
June 18, 2025
REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced the pricing of its previously announced underwritten public offering consisting of (i) 19, …
Participation in “The 113th Congress of Japan Society of Aesthetic Surgery,” May 2025
GlobeNewswire
·
June 18, 2025
IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”) today announced that a total of 22 representatives, including Yoshiyuki Aikawa, CEO of SBC Medical, and doctors from Shonan Beauty …
UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42
GlobeNewswire
·
June 18, 2025
HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- This press release has been updated to reflect the correct timing of the funding round. Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its …